Share
Other content recommended for you
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- What is CAR T-cell therapy?
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Cardiotoxicities of novel cancer immunotherapies
- CAR-T treatment for hematological malignancies
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know